Flumazenil for hepatic encephalopathy grade III and IVa in patients with cirrhosis: An Italian multicenter double-blind, placebo-controlled, cross- over study

Hepatology

Volumn 28, Issue 2, 1998, Pages 374-378

  Barbaro, Gluseppe ^a,g   Di Lorenzo, Gabriella ^a   Soldini, Maurizio ^a   Giancaspro, Giuseppe ^a   Bellomo, Giorgio ^b   Belloni, Giancarlo ^c   Grisorio, Benvenuto ^d   Annese, Mauro ^e   Bacca, Donato ^f   Francavilla, Ruggiero ^f   Barbarini, Giorgio ^c  

^a SAPIENZA UNIVERSITY OF ROME   (Italy)

^b UNIVERSITY OF TURIN   (Italy)

^c UNIVERSITY OF PAVIA   (Italy)

^d GENERAL HOSPITAL   (Italy)

^e General Hospital   (Italy)

^f GENERAL HOSPITAL   (Italy)

^g NONE   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

BENZODIAZEPINE RECEPTOR BLOCKING AGENT; FLUMAZENIL; PLACEBO;

ADULT; AGED; ARTICLE; CLINICAL TRIAL; CONTROLLED STUDY; CROSSOVER PROCEDURE; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; ELECTROENCEPHALOGRAM; FEMALE; HEPATIC ENCEPHALOPATHY; HUMAN; LIVER CIRRHOSIS; LIVER DISEASE; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; NEUROLOGICAL COMPLICATION; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; TREATMENT OUTCOME;

ADULT; AGED; BENZODIAZEPINES; CROSS-OVER STUDIES; DOUBLE-BLIND METHOD; FEMALE; FLUMAZENIL; GABA MODULATORS; HEPATIC ENCEPHALOPATHY; HUMANS; ITALY; LIVER CIRRHOSIS; MALE; MIDDLE AGED; NERVOUS SYSTEM; TREATMENT OUTCOME;

EID: 7344248987     PISSN: 02709139     EISSN: None     Source Type: Journal    
DOI: 10.1002/hep.510280212     Document Type: Article

References (28)

1. Basile AS, Jones EA. Hepatic encephalopathy and the GABA-benzodiazepine receptor-chloride ionophore complex: an update. J Gastroenterol Hepatol 1988;3:387-388.
2. Mullen KD, Szauter KM, Kaminsky-Russ K. Endogenous benzodiaz-epine activity in body fluids of patients with hepatic encephalopathy. Lancet 1990;336:81-83.
3. Ritz R, Zuber M, Elsasser S, Scollo-Lavizzari C. Use of flumazenil in intoxication patients with coma. A double-blind placebo-controlled study in ICU. Intensive Care Med 1990;16:242-247.
4. Hoger J, Baehrendtz S, Matell G, Gustafsson LL. Diagnostic utility of flumazenil in coma with suspected poisoning: a double-blind randomized controlled study. BMJ 1990;301:1308-1311.
5. Grimm G, Katzenschlager R, Schneeweiss B, Lenz K, Ferenci P, Madl C, Laggner AN, et al. Improvement of hepatic encephalopathy treated with flumazenil. Lancet 1988;2:1391-1394.
6. Bansky G, Meier PJ, Ziegler WH, Waiser H, Schmid M, Huber M. Reversal of hepatic coma by benzodiazepine antagonist (RO 15-1788). Lancet 1985;i:1324-1325.
7. Klotz U, Walker S. Flumazenil and hepatic encephalopathy. Lancet 1989;i:155-156.
8. Pomier-Layrargues G, Giguere JF, Lavoie J, Perney P, Gagnon S, D'Amour M, Wells J, et al. Flumazenil in cirrhotic patients with hepatic encephalopathy: a randomized double-blind placebo-controlled crossover trial. HEPATOLOGY 1994;19:31-37.
9. Cadranel JF, El Younsi M, Pidoux B, Zylberberg P, Benhamou Y, Valla D, Opolon P. Flumazenil therapy for hepatic encephalopathy in cirrhotic patients: a double-blind pragmatic randomized, placebo study. Eur J Gatroenterol Hepatol 1995;7:325-329.
10. Barbaro G, Di Lorenzo G, Soldini M, Marziali M, Bellomo G, Belloni G, Annese M, et al. Flumazenil for hepatic coma in patients with liver cirrhosis: an Italian multicenter double-blind, placebo-controlled, cross-over study. HEPATOLOGY 1997;26(S4):182A.
11. Grippon P, Opolon P. Insuffisance hepatocellulaire aigue. Paris: Encycl. Med. Chir (Foie-Pancrias), 1988;7014:14.
12. Pappas SC, Jones EA. Methods of assessing hepatic encephalopathy. Semin Liver Dis 1983;3:298-307.
13. Spehlman R. EEG Primer. 2nd ed. New York: Eisevier, 1991:403-440.
14. Falkner FC, Sweetman BJ, Watson JT. Biomedical applications of selected ion monitoring. Applied Spectroscopy Review 1975;10:51-61.
15. Armitage P, Berry G. Statistical methods in medical research, 3rd ed. Oxford: Blackwell Scientific, 1994.
16. Mullen KD, Martin JV, Mendelson WB, Bassett ML, Jones EA. Could an endogenous benzodiazepine ligand contribute to hepatic encephalopathy? Lancet 1988;i:457-459.
17. Brogden RN, Goa KL. Flumazenil: a preliminary review of the benzodiazepine antagonist properties, intrinsic activity and therapeutic use. Drugs 1988;35:448-457.
18. Scollo-Lavizzari G, Steinmann E. Reversal of hepatic coma by benzodiazepine antagonist (RO 15-1788). Lancet 1985;i:1324.
19. Burke DA, Mitchell KW, AI Mardini H, Record CO. Reversal of hepatic coma with flumazenil. Improvement in visual evoked potentials. Lancet 1988;ii:505-506.
20. Meier R, Gyr K. Treatment of hepatic encephalopathy (HE) with the benzodiazepine antagonist flumazenil: a pilot study. Eur J Anaesthesiol 1988;(Suppl 2):139-146.
21. Sutherland LR, Minuk GY. RO 15-1788 and hepatic failure. Ann Intern Med 1988;108:158.
22. Bansky G, Meier PJ, Riederer E, Waiser H, Ziegler WH, Schmid M. Effect of the benzodiazepine receptor antagonist flumazenil in hepatic encephalopathy in humans. Gastroenterology 1989;97:744-750.
23. Pidoux B, Zylberberg P, Valla D, Opolon P. Etude hlectroencepha-lographique de l'effet d'un antagoniste des benzodiazepines dans l'encephalopathie hepatique. Neurophysiol Clin 1989;19:469-476.
24. Viel E, De La Cous'saye JE, Bassou LB, Saissi G, Elediam JJ. Traitement de l'encephalopathie hèpatique aigue par le flumazenil. Ann Fr Anesth Reanim 1990;9:386-389.
25. Marsepoil T, Hermant JL, Ho P, Blin F, levesque P. Traitement de l'encephalopathie hepatique par le flumazenil. Ann Fr Anesth Rhanim 1990;9:399-400.
26. Samson Y, Bernuau J, Pappata S, Chavoix C, Baron JC, Maziere MA. Cerebral uptake of benzodiazepine measured by positron emission tomography in hepatic encephalopalhy. N Engl J Med 1987;316:414-415.
27. Pomier-Layrargues G, Giguere JF, Lavoie J, Willems B, Butterworth RE Pharmacokinetics of benzodiazepine antagonist RO 15-1788 in cirrhotic patients with moderate or severe liver dysfunction. HEPATOLOGY 1989;10: 969-972.
28. File SE, Pellow S. Intrinsic actions of the benzodiazepine receptor antagonist RO 15-1788. Psychopharmacology 1986;88:1-11.